tiprankstipranks
Biohaven Ltd. (BHVN)
NYSE:BHVN
US Market
BHVN
Biohaven Ltd.
RESEARCH TOOLSreports
Want to see BHVN full AI Analyst Report?

Biohaven Ltd. (BHVN) Stock Forecast & Price Target

856 Followers
See the Price Targets and Ratings of:

BHVN Analyst Ratings

Moderate Buy
12Ratings
Moderate Buy
8 Buy
4 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Biohaven
Ltd.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BHVN Stock 12 Month Forecast

Average Price Target

$19.60
▲(78.51% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Biohaven Ltd. in the last 3 months. The average price target is $19.60 with a high forecast of $30.00 and a low forecast of $9.00. The average price target represents a 78.51% change from the last price of $10.98.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","31":"$31","13.75":"$13.75","19.5":"$19.5","25.25":"$25.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,13.75,19.5,25.25,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.63,11.196923076923078,12.763846153846155,14.330769230769231,15.897692307692306,17.464615384615385,19.03153846153846,20.598461538461535,22.165384615384614,23.732307692307693,25.299230769230768,26.866153846153843,28.433076923076918,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.63,10.396923076923077,11.163846153846155,11.930769230769231,12.697692307692309,13.464615384615385,14.231538461538463,14.99846153846154,15.765384615384615,16.532307692307693,17.29923076923077,18.066153846153846,18.833076923076923,{"y":19.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.63,9.581538461538463,9.533076923076925,9.484615384615385,9.436153846153847,9.387692307692308,9.33923076923077,9.29076923076923,9.242307692307692,9.193846153846154,9.145384615384616,9.096923076923076,9.048461538461538,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.96,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.89,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.82,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.32,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.29,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.75,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.81,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.62,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.63,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$30.00Average Price Target$19.60Lowest Price Target$9.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on BHVN
Unknown Analyst
Bernstein
Not Ranked
Bernstein
$9
Hold
-18.03%
Downside
Reiterated
05/13/26
Biohaven Ltd. (BHVN) Receives a Hold from Bernstein
Morgan Stanley Analyst forecast on BHVN
Terence Flynn
Morgan Stanley
Morgan Stanley
$21→$18
Buy
63.93%
Upside
Assigned
05/13/26
Biohaven price target lowered to $18 from $21 at Morgan StanleyBiohaven price target lowered to $18 from $21 at Morgan Stanley
H.C. Wainwright Analyst forecast on BHVN
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$10
Hold
-8.93%
Downside
Reiterated
05/12/26
Biohaven: Hold Rating Reiterated as Clinical and Competitive Uncertainties Persist; Price Target Maintained at $10
William Blair Analyst forecast on BHVN
Myles Minter
William Blair
William Blair
―
Hold
―
Reiterated
05/05/26
Analysts Conflicted on These Healthcare Names: Crispr Therapeutics AG (NASDAQ: CRSP) and Biohaven Ltd. (NYSE: BHVN)
TD Cowen Analyst forecast on BHVN
Tyler Van Buren
TD Cowen
TD Cowen
$30
Buy
173.22%
Upside
Reiterated
05/04/26
Biohaven: Buy Rating Reiterated as Pipeline De‑Risking Builds Ahead of Key 2026 Readouts; $30 Price Target Maintained
RBC Capital Analyst forecast on BHVN
Leonid Timashev
RBC Capital
RBC Capital
$23→$22
Buy
100.36%
Upside
Assigned
05/04/26
Biohaven Ltd. (BHVN) Gets a Buy from RBC Capital
Canaccord Genuity Analyst forecast on BHVN
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$21
Buy
91.26%
Upside
Reiterated
05/04/26
Biohaven: Buy Rating Reiterated as Analyst Sees Multiple Pipeline Catalysts and Maintains $21 Price Target
Bank of America Securities Analyst forecast on BHVN
Dina Ramadane
Bank of America Securities
Bank of America Securities
$14→$12
Hold
9.29%
Upside
Reiterated
05/04/26
Biohaven Price Target Trimmed to $12 as Analyst Maintains Hold Amid Balanced Pipeline Upside and Financing Risks
Citi Analyst forecast on BHVN
Samantha Semenkow
Citi
Citi
$14→$17
Buy
54.83%
Upside
Reiterated
04/02/26
Biohaven price target raised to $17 from $14 at CitiBiohaven price target raised to $17 from $14 at Citi
Piper Sandler Analyst forecast on BHVN
Allison Bratzel
Piper Sandler
Piper Sandler
$30
Buy
173.22%
Upside
Reiterated
03/24/26
Biohaven Ltd. (BHVN) Gets a Buy from Piper Sandler
Goldman Sachs Analyst forecast on BHVN
Corinne Johnson
Goldman Sachs
Goldman Sachs
$24→$27
Buy
145.90%
Upside
Reiterated
03/10/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN), Biohaven Ltd. (NYSE: BHVN) and Teladoc (NYSE: TDOC)
Raymond James Analyst forecast on BHVN
Christopher Raymond
Raymond James
Raymond James
―
Buy
―
Reiterated
03/09/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
J.P. Morgan Analyst forecast on BHVN
Tessa Romero
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
12/26/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Novavax (NASDAQ: NVAX), Xenon (NASDAQ: XENE) and Biohaven Ltd. (NYSE: BHVN)
Leerink Partners Analyst forecast on BHVN
Marc Goodman
Leerink Partners
Leerink Partners
$50→$15
Buy
36.61%
Upside
Reiterated
12/25/25
Biohaven: MDD Setback but Epilepsy Refocus and Diversified Pipeline Support Continued Buy Rating
UBS Analyst forecast on BHVN
Ashwani Verma
UBS
UBS
$26→$11
Hold
0.18%
Upside
Downgraded
11/28/25
Cautious Hold Rating on Biohaven Ltd. Amidst R&D Setbacks and Competitive Challenges
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on BHVN
Unknown Analyst
Bernstein
Not Ranked
Bernstein
$9
Hold
-18.03%
Downside
Reiterated
05/13/26
Biohaven Ltd. (BHVN) Receives a Hold from Bernstein
Morgan Stanley Analyst forecast on BHVN
Terence Flynn
Morgan Stanley
Morgan Stanley
$21→$18
Buy
63.93%
Upside
Assigned
05/13/26
Biohaven price target lowered to $18 from $21 at Morgan StanleyBiohaven price target lowered to $18 from $21 at Morgan Stanley
H.C. Wainwright Analyst forecast on BHVN
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$10
Hold
-8.93%
Downside
Reiterated
05/12/26
Biohaven: Hold Rating Reiterated as Clinical and Competitive Uncertainties Persist; Price Target Maintained at $10
William Blair Analyst forecast on BHVN
Myles Minter
William Blair
William Blair
―
Hold
―
Reiterated
05/05/26
Analysts Conflicted on These Healthcare Names: Crispr Therapeutics AG (NASDAQ: CRSP) and Biohaven Ltd. (NYSE: BHVN)
TD Cowen Analyst forecast on BHVN
Tyler Van Buren
TD Cowen
TD Cowen
$30
Buy
173.22%
Upside
Reiterated
05/04/26
Biohaven: Buy Rating Reiterated as Pipeline De‑Risking Builds Ahead of Key 2026 Readouts; $30 Price Target Maintained
RBC Capital Analyst forecast on BHVN
Leonid Timashev
RBC Capital
RBC Capital
$23→$22
Buy
100.36%
Upside
Assigned
05/04/26
Biohaven Ltd. (BHVN) Gets a Buy from RBC Capital
Canaccord Genuity Analyst forecast on BHVN
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$21
Buy
91.26%
Upside
Reiterated
05/04/26
Biohaven: Buy Rating Reiterated as Analyst Sees Multiple Pipeline Catalysts and Maintains $21 Price Target
Bank of America Securities Analyst forecast on BHVN
Dina Ramadane
Bank of America Securities
Bank of America Securities
$14→$12
Hold
9.29%
Upside
Reiterated
05/04/26
Biohaven Price Target Trimmed to $12 as Analyst Maintains Hold Amid Balanced Pipeline Upside and Financing Risks
Citi Analyst forecast on BHVN
Samantha Semenkow
Citi
Citi
$14→$17
Buy
54.83%
Upside
Reiterated
04/02/26
Biohaven price target raised to $17 from $14 at CitiBiohaven price target raised to $17 from $14 at Citi
Piper Sandler Analyst forecast on BHVN
Allison Bratzel
Piper Sandler
Piper Sandler
$30
Buy
173.22%
Upside
Reiterated
03/24/26
Biohaven Ltd. (BHVN) Gets a Buy from Piper Sandler
Goldman Sachs Analyst forecast on BHVN
Corinne Johnson
Goldman Sachs
Goldman Sachs
$24→$27
Buy
145.90%
Upside
Reiterated
03/10/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN), Biohaven Ltd. (NYSE: BHVN) and Teladoc (NYSE: TDOC)
Raymond James Analyst forecast on BHVN
Christopher Raymond
Raymond James
Raymond James
―
Buy
―
Reiterated
03/09/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
J.P. Morgan Analyst forecast on BHVN
Tessa Romero
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
12/26/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Novavax (NASDAQ: NVAX), Xenon (NASDAQ: XENE) and Biohaven Ltd. (NYSE: BHVN)
Leerink Partners Analyst forecast on BHVN
Marc Goodman
Leerink Partners
Leerink Partners
$50→$15
Buy
36.61%
Upside
Reiterated
12/25/25
Biohaven: MDD Setback but Epilepsy Refocus and Diversified Pipeline Support Continued Buy Rating
UBS Analyst forecast on BHVN
Ashwani Verma
UBS
UBS
$26→$11
Hold
0.18%
Upside
Downgraded
11/28/25
Cautious Hold Rating on Biohaven Ltd. Amidst R&D Setbacks and Competitive Challenges
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Biohaven Ltd.

3 Months
xxx
Success Rate
10/22 ratings generated profit
45%
Average Return
+6.10%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of +6.10% per trade.
1 Year
Thomas ShraderBTIG
Success Rate
10/22 ratings generated profit
45%
Average Return
+18.68%
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +18.68% per trade.
2 Years
xxx
Success Rate
5/22 ratings generated profit
23%
Average Return
-28.77%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 22.73% of your transactions generating a profit, with an average return of -28.77% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BHVN Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
16
4
10
11
13
Buy
5
5
3
2
1
Hold
12
5
7
5
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
33
14
20
18
23
In the current month, BHVN has received 14 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. BHVN average Analyst price target in the past 3 months is 19.60.
Each month's total comprises the sum of three months' worth of ratings.

BHVN Financial Forecast

BHVN Earnings Forecast

Next quarter’s earnings estimate for BHVN is -$0.74 with a range of -$0.89 to -$0.55. The previous quarter’s EPS was -$0.88. BHVN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BHVN has Performed in-line its overall industry.
Next quarter’s earnings estimate for BHVN is -$0.74 with a range of -$0.89 to -$0.55. The previous quarter’s EPS was -$0.88. BHVN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BHVN has Performed in-line its overall industry.
No data currently available

BHVN Sales Forecast

Next quarter’s sales forecast for BHVN is $490.00K with a range of $0.00 to $5.89M. The previous quarter’s sales results were $0.00. BHVN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BHVN has Performed in-line its overall industry.
Next quarter’s sales forecast for BHVN is $490.00K with a range of $0.00 to $5.89M. The previous quarter’s sales results were $0.00. BHVN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BHVN has Performed in-line its overall industry.

BHVN Stock Forecast FAQ

What is BHVN’s average 12-month price target, according to analysts?
Based on analyst ratings, Biohaven Ltd.’s 12-month average price target is 19.60.
    What is BHVN’s upside potential, based on the analysts’ average price target?
    Biohaven Ltd. has 78.51% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BHVN a Buy, Sell or Hold?
          Biohaven Ltd. has a consensus rating of Moderate Buy which is based on 8 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Biohaven Ltd.’s price target?
            The average price target for Biohaven Ltd. is 19.60. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $30.00 ,the lowest forecast is $9.00. The average price target represents 78.51% Increase from the current price of $10.98.
              What do analysts say about Biohaven Ltd.?
              Biohaven Ltd.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of BHVN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.